20/20 BIOLABS, INC. Financing Cash Flow
20/20 BIOLABS, INC. (AIDX) reported Financing Cash Flow of $5.43 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- 20/20 BIOLABS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $940.00K.
- 20/20 BIOLABS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $4.49M, a 1610.55% increase year-over-year.
- 20/20 BIOLABS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-06-30 was $0.00.
- 20/20 BIOLABS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-03-31 was $262.34K.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|
| 2026-06-30 | $940.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $5.43M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $4.49M 10-Q · filed 2026-05-20 | ||
| 2025-12-31 | $1.16M POS AM · filed 2026-04-06 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $262.34K 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $262.34K 10-Q · filed 2026-05-20 | ||
| 2024-12-31 | $293.33K POS AM · filed 2026-04-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGENOMICS INC (NEO) | United States | $2.514B | -35.96 |